ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-88-166-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees130
OptionableOptionable
ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions
What is ProQR Therapeutics' stock symbol?
ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics' earnings last quarter?
ProQR Therapeutics NV (NASDAQ:PRQR) announced its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.10. View ProQR Therapeutics' Earnings History.
When is ProQR Therapeutics' next earnings date?
What price target have analysts set for PRQR?
6 analysts have issued 1-year price objectives for ProQR Therapeutics' shares. Their predictions range from $20.00 to $40.00. On average, they expect ProQR Therapeutics' share price to reach $29.60 in the next twelve months. This suggests a possible upside of 91.8% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.
What is the consensus analysts' recommendation for ProQR Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.
What are Wall Street analysts saying about ProQR Therapeutics stock?
Here are some recent quotes from research analysts about ProQR Therapeutics stock:
- 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (1/9/2019)
- 2. Cantor Fitzgerald analysts commented, "We think the company’s RNA-based platform for inherited eye diseases has significant potential. The company established the initial proof of concept for their approach this past September. QR-110, the company’s lead ophthalmology asset, led to meaningful vision improvements in patients with a specific type of inherited blindness called LCA10. The company is applying this approach to many additional genetic eye diseases. For instance, we model peak sales potential of $1.1B for QR-411 which are being studied in other inherited forms of blindness." (12/13/2018)
- 3. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $18.0/ share, as a 25x multiple of taxed and diluted $9.92 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.9/ share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (10/30/2018)
Has ProQR Therapeutics been receiving favorable news coverage?
News stories about PRQR stock have trended very positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProQR Therapeutics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Are investors shorting ProQR Therapeutics?
ProQR Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,862,748 shares, an increase of 75.2% from the December 14th total of 1,063,212 shares. Based on an average daily volume of 705,526 shares, the short-interest ratio is currently 2.6 days. Approximately 7.1% of the shares of the stock are sold short. View ProQR Therapeutics' Current Options Chain.
Who are some of ProQR Therapeutics' key competitors?
Some companies that are related to ProQR Therapeutics include Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Insmed (INSM) and Madrigal Pharmaceuticals (MDGL).
Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the folowing people:
- Mr. Daniel A. de Boer, CEO & Member of Management Board (Age 35)
- Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Sec. & Member of Management Board (Age 54)
- Ms. Smital Shah, Chief Financial Officer (Age 42)
- Mr. Joost Clement, Director of HR
- Mr. Bart Klein, Sr. VP of Intellectual Property
How do I buy shares of ProQR Therapeutics?
Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics' stock price today?
One share of PRQR stock can currently be purchased for approximately $15.43.
How big of a company is ProQR Therapeutics?
ProQR Therapeutics has a market capitalization of $597.38 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 130 workers across the globe.
What is ProQR Therapeutics' official website?
How can I contact ProQR Therapeutics?
ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]
MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
